Formycon AG
XETRA: FYB.DE0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Deutsche Börse
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Stefan Glombitza
- Employees
- 250
- Headquarters
- Planegg, Germany
- IPO year
- 2011
- Market cap
- €332.3M
- Website
- https://www.formycon.com
Loading FYB…
Loading profile data…Frequently asked questions about FYB
What does Formycon AG (FYB.DE) do?
Formycon AG develops and markets biosimilar products. Its product pipeline includes FYB201, a biosimilar candidate for Lucentis, an ophthalmic drug used in the treatment of neovascular age-related macular degeneration and other serious eye diseases; FYB202, a biosimilar candidate for Stelara, a biopharmaceutical used in the treatment of inflamma...
Where does FYB.DE trade?
Formycon AG (FYB.DE) trades on the Deutsche Börse.
What sector is FYB.DE in?
Formycon AG (FYB.DE) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Formycon AG?
Stefan Glombitza is the chief executive officer of Formycon AG (FYB.DE).
Where is Formycon AG headquartered?
Formycon AG is headquartered in Germany.
Does FYB.DE pay a dividend?
Formycon AG (FYB.DE) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did FYB.DE go public?
Formycon AG (FYB.DE) completed its initial public offering in 2011.